Literature DB >> 17694085

HDAC3: taking the SMRT-N-CoRrect road to repression.

P Karagianni1, J Wong.   

Abstract

Known histone deacetylases (HDACs) are divided into different classes, and HDAC3 belongs to Class I. Through forming multiprotein complexes with the corepressors SMRT and N-CoR, HDAC3 regulates the transcription of a plethora of genes. A growing list of nonhistone substrates extends the role of HDAC3 beyond transcriptional repression. Here, we review data on the composition, regulation and mechanism of action of the SMRT/N-CoR-HDAC3 complexes and provide several examples of nontranscriptional functions, to illustrate the wide variety of physiological processes affected by this deacetylase. Furthermore, we discuss the implication of HDAC3 in cancer, focusing on leukemia. We conclude with some thoughts about the potential therapeutic efficacies of HDAC3 activity modulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17694085     DOI: 10.1038/sj.onc.1210612

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  111 in total

1.  Alternative mRNA splicing of corepressors generates variants that play opposing roles in adipocyte differentiation.

Authors:  Michael L Goodson; Brenda J Mengeling; Brian A Jonas; Martin L Privalsky
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

Review 2.  Histone deacetylases in kidney development: implications for disease and therapy.

Authors:  Shaowei Chen; Samir S El-Dahr
Journal:  Pediatr Nephrol       Date:  2012-06-22       Impact factor: 3.714

3.  HDAC3 selectively represses CREB3-mediated transcription and migration of metastatic breast cancer cells.

Authors:  Han-Cheon Kim; Kyung-Chul Choi; Hyo-Kyoung Choi; Hee-Bum Kang; Mi-Jeong Kim; Yoo-Hyun Lee; Ok-Hee Lee; Jeongmin Lee; Young Jun Kim; Woojin Jun; Jae-Wook Jeong; Ho-Geun Yoon
Journal:  Cell Mol Life Sci       Date:  2010-05-15       Impact factor: 9.261

4.  Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung.

Authors:  Yoshihiro Minamiya; Takashi Ono; Hajime Saito; Naoko Takahashi; Manabu Ito; Satoru Motoyama; Junichi Ogawa
Journal:  Tumour Biol       Date:  2010-06-19

5.  Hdac3 is essential for the maintenance of chromatin structure and genome stability.

Authors:  Srividya Bhaskara; Sarah K Knutson; Guochun Jiang; Mahesh B Chandrasekharan; Andrew J Wilson; Siyuan Zheng; Ashwini Yenamandra; Kimberly Locke; Jia-Ling Yuan; Alyssa R Bonine-Summers; Christina E Wells; Jonathan F Kaiser; M Kay Washington; Zhongming Zhao; Florence F Wagner; Zu-Wen Sun; Fen Xia; Edward B Holson; Dineo Khabele; Scott W Hiebert
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

6.  HDAC3 is negatively regulated by the nuclear protein DBC1.

Authors:  Claudia C S Chini; Carlos Escande; Veronica Nin; Eduardo N Chini
Journal:  J Biol Chem       Date:  2010-10-28       Impact factor: 5.157

7.  Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.

Authors:  Derek S Welsbie; Jin Xu; Yu Chen; Laetitia Borsu; Howard I Scher; Neal Rosen; Charles L Sawyers
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

8.  Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.

Authors:  C James Chou; David Herman; Joel M Gottesfeld
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

9.  The polycomb group gene Bmi1 regulates antioxidant defenses in neurons by repressing p53 pro-oxidant activity.

Authors:  Wassim Chatoo; Mohamed Abdouh; Jocelyn David; Marie-Pier Champagne; José Ferreira; Francis Rodier; Gilbert Bernier
Journal:  J Neurosci       Date:  2009-01-14       Impact factor: 6.167

Review 10.  Deconstructing repression: evolving models of co-repressor action.

Authors:  Valentina Perissi; Kristen Jepsen; Christopher K Glass; Michael G Rosenfeld
Journal:  Nat Rev Genet       Date:  2010-02       Impact factor: 53.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.